

## Original Article

# Atorvastatin does not Affect Ischaemia-Induced Phosphatidylserine Exposition in Humans *in-vivo*

Constantijn W. Wouters<sup>1,2</sup>, Patrick Meijer<sup>1,3</sup>, Carola I.F. Janssen<sup>1</sup>, Geert W.J. Frederix<sup>1</sup>, Wim J. Oyen<sup>4</sup>, Otto C. Boerman<sup>4</sup>, Paul Smits<sup>1,5</sup> and Gerard A. Rongen<sup>1,5</sup>

<sup>1</sup>Department of Pharmacology-Toxicology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

<sup>2</sup>Department of Cardiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

<sup>3</sup>Department of Anaesthesiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

<sup>4</sup>Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

<sup>5</sup>Department of General Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

**Aim:** Statins can induce pharmacologic preconditioning and thereby reduce infarct size. Cellular phosphatidylserine (PS) exposition occurs in the course of ischaemia and reperfusion and has been associated with injury. In this experiment we studied the effect of atorvastatin on PS exposition after a standardised ischaemia and reperfusion challenge.

**Methods:** In a double-blind randomised cross-over trial 30 healthy volunteers were allocated to 3 day treatment with atorvastatin (80 mg/day) and placebo ( $n=24$ ), or placebo treatment twice ( $n=6$ ). At the end of each treatment period, volunteers underwent 10 minutes of forearm ischaemic exercise. At reperfusion radiolabeled annexin A5 was administered intravenously and Gamma camera imaging of both hands was performed 1 and 4 hours after reperfusion.

**Results:** Annexin A5 targeting was not different between atorvastatin treatment ( $26.1 \pm 9.8\%$  and  $24.0 \pm 9.5\%$  respectively at 1 and 4 hours after reperfusion) and placebo treatment ( $25.6 \pm 11.0\%$  and  $24.5 \pm 10.7\%$ ) ( $p=0.99$ ). Our time control experiment did not reveal a carry-over effect.

**Conclusions:** Our results show that treatment with atorvastatin 80 mg does not reduce forearm PS exposition after ischaemic exercise. This suggests that the role of PS exposure in the prevention of ischemia and reperfusion injury by short term treatment with atorvastatin is limited.

*J Atheroscler Thromb, 2012; 19:285-291.*

**Key words;** Atorvastatin, Ischaemia-reperfusion injury, Phosphatidylserines, Annexin A5 scintigraphy, Pharmacologic preconditioning

## Introduction

The cholesterol lowering action of statins (HMG-coenzyme A reductase inhibitors) and its associated reduction in cardiovascular events have been well documented in numerous clinical trials<sup>1-4</sup>. Traditionally, this beneficial effect of statins has been explained by lowering of plasma cholesterol and sub-

sequent reduced progression of atherosclerosis. Apart from its cholesterol lowering properties, statins have other ("pleiotropic") actions, such as up-regulation of ecto-5'-nucleotidase<sup>5-7</sup>, activation of the phosphatidylinositol 3-kinase-Akt pathway<sup>8</sup> and up-regulation of NO synthase<sup>9, 10</sup> which all may increase tolerance against ischaemia and reperfusion (IR)<sup>11-13</sup>. Several animal studies have shown reduction of IR-injury as a result of statin treatment in both the heart and the kidney<sup>14-17</sup>. This putative protection may explain the clinical observation that early initiation of statin treatment in patients with an acute cardiovascular event improves long-term prognosis as compared with a delayed start of this treatment<sup>18-20</sup>. Furthermore in two randomised clinical trials one day treatment with

Address for correspondence: Gerard A. Rongen, Department of Pharmacology-Toxicology, Radboud University Nijmegen Medical Centre, p/o box 9101, 6500 HB Nijmegen, The Netherlands

E-mail: g.rongen@pharmtox.umcn.nl

Received: July 1, 2011

Accepted for publication: September 20, 2011

atorvastatin prior to percutaneous coronary intervention reduced myocardial injury and improved clinical outcomes in patients with acute coronary syndromes<sup>21, 22</sup>).

Ischaemia induced phosphatidylserine (PS) exposure on cardiomyocytes has been associated with reversible cellular damage and apoptosis<sup>23, 24</sup>. Treatment to shield exposed PS with diannexin, a homodimer of human annexin A5 (with high affinity for exposed phosphatidylserines) significantly reduces IR-injury in the liver and kidney<sup>25, 26</sup>. Likewise, diannexin prevents no-reflow in a rabbit cardiac ischemia-reperfusion model<sup>27</sup>. These observations suggest a critical role for exposed PS in the development of IR-injury. We have developed an experimental model to study PS exposure after IR in healthy volunteers. Our model uses radiolabeled recombinant annexin A5 to visualise PS-exposition that occurs after 10 minutes of forearm ischemia combined with isometric exercise<sup>28</sup>. Interventions that have been shown in preclinical and clinical research to modulate myocardial infarct size (ischemic preconditioning, and administration of adenosine, dipyridamole, and caffeine) similarly modulate annexin A5 targeting in our forearm model, further supporting a role for PS-exposure in IR-injury<sup>28-30</sup>.

Using annexin A5 scintigraphy after voluntary ischaemic exercise in healthy males, we have recently shown that annexin A5 targeting after a short pretreatment with rosuvastatin 20 mg once daily was significantly reduced ( $16 \pm 1\%$  and  $18 \pm 2\%$  respectively at 1 and 4 hours after reperfusion) compared to placebo treatment ( $21 \pm 3\%$  and  $25 \pm 3\%$ ) ( $p < 0.05$ )<sup>31</sup>. As previously reported for other statins in preclinical research with infarct size as endpoint, this effect of rosuvastatin was inhibited by caffeine, an adenosine receptor antagonist<sup>31</sup>.

There is ample evidence from animal and clinical research that treatment for three days with high dose atorvastatin protects against IR-injury<sup>15, 21, 32-34</sup>. However, we do not know whether PS exposure relates to this clinical benefit of atorvastatin, as differences have been observed in the efficacy of various statins to inhibit HMG-CoA-reductase<sup>35</sup> and to induce pleiotropic effects<sup>36</sup>.

## Aim


We aim to assess the role of PS-modulation in the beneficial effect of atorvastatin on IR-injury. We tested the hypothesis that a short pretreatment with atorvastatin 80 mg reduces annexin A5 targeting in our forearm IR-model.

## Methods

After approval of the protocol (NCT00441597) by the Institutional Review Board of the Radboud University Nijmegen Medical Centre and in accordance with the declaration of Helsinki (2008), 30 healthy male volunteers (age 18-54) signed informed consent. All participants underwent medical screening to exclude cardiovascular disease, hypercholesterolemia, hypertension, diabetes mellitus, and impaired renal function. Furthermore serum values of creatinin kinase (CK) and alanine aminotransferase (ALT) were measured to exclude participants possibly at risk for adverse events due to atorvastatin use (rhabdomyolysis and toxic hepatitis).

In this double blind randomised cross-over trial (**Fig. 1**) participants were allocated to treatment with either atorvastatin and placebo ( $n=24$ ), or placebo treatment twice ( $n=6$ ). The latter group served as a time-control. Furthermore, it allowed us to verify our assumptions on within subject variability and test-to-test correlation of our annexin A5 scans. Placebo or atorvastatin (80 mg) was administered for three days, and at least 4 weeks were allowed between the two treatment periods as a wash-out. Atorvastatin 80mg (Pfizer, Capelle a/d IJssel, The Netherlands) was encapsulated to match placebo by the department of Clinical Pharmacy (Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands according to GMP standards). In both treatment periods the first tablet was administered under supervision of the investigator, after venous blood sampling to determine fasting lipid profile. The participant was instructed to take the second capsule in the morning and to abstain from caffeine during the last 24 hours prior to ischaemic exercise. On day 3 after an overnight fast the last tablet was administered under supervision, again after assessment of fasting lipid profile and serum caffeine level to verify protocol compliance.

Sixty minutes after administration of the study medication in all participants maximal voluntary contraction force of the non-dominant forearm was measured with an isometric handgrip dynamometer. Subsequently, the circulation of the non-dominant forearm was occluded for 10 minutes with an upper arm cuff inflated to 200 mmHg. Directly after occlusion volunteers were asked to perform isometric contractions of the finger flexors at 50% of their maximum contraction force. These contractions were performed rhythmically with 5 seconds of contraction followed by 5 seconds of relaxation until exhaustion. The total duration of ischaemia was 10 minutes, independent of the duration of contractions.



**Fig. 1.** Study protocol. From the 30 participants 12 were randomised to 3 days of atorvastatin treatment followed by three days of placebo treatment. 12 Participants were randomised to first 3 days of placebo treatment and next 3 days atorvastatin treatment, and 6 participants were randomised to placebo treatment twice. At day three of treatment participants performed 10 minutes of ischemic forearm exercise. Upon reperfusion Tc-99m labelled annexin A5 was administered and scintigraphy was performed 1 and 4 hours after reperfusion. Between both treatment periods a 4 week interval was observed.

Immediately upon reperfusion 100 microgram recombinant human annexin A5, radiolabeled with 450 MBq Technetium-99m was administered intravenously into the dominant arm. One and four hours after this administration both hands were scanned simultaneously by use of a gamma camera (Orbiter camera equipped with low-energy high-resolution collimators; Siemens, Hoffman Estates, Ill, USA) as previously described<sup>28</sup>.

Caffeine plasma concentrations were determined using reversed-phase HPLC with UV detection set at 273 nm<sup>37</sup>. Serum lipid profile (total-, HDL- and LDL-cholesterol and triglycerides), creatinine kinase (CK) and alanine amino transferase (ALAT) were determined with a commercially available kit (Aeroset, Abbott, Santa Clara, Cal., USA).

### Data Analysis

All the digitised gamma camera images were analysed offline by the same investigator (W.J.O.) using Hermes software (Nuclear Diagnostics, Stockholm, Sweden). A predefined region of interest was placed over the thenar muscle of both hands. Annexin A5 targeting was expressed as the percentage difference in counts/pixel between the experimental (non-dominant) hand and the control hand as previously described<sup>28</sup>.

### Statistical Analysis

Values are expressed as mean  $\pm$  standard error (SE) unless indicated otherwise.

This study is the first to use our forearm IR-model in a paired set-up in healthy volunteers. Based on previous studies, a between subject SD of 10% was predicted<sup>28-30</sup>. Conservatively assuming a correlation coefficient of 0.5 between first and second paired observation, we calculated that with an alpha of 0.05 and a power of 90%, using 24 subjects allows us to find a difference in annexin A5 targeting of 7%. This is well in the range of our previous observation after treatment with rosuvastatin<sup>31</sup>. Furthermore 6 additional participants were randomised (in a double-blind fashion) to receive placebo treatment twice to serve as time control experiment. This time-control allows us to verify our assumptions regarding this power analysis afterwards.

The effect of atorvastatin treatment on annexin A5 targeting and lipid profile was tested using ANOVA for repeated measurements. All statistical analyses were performed using SPSS 16.0 for Windows.

### Results

Baseline characteristics of all participants are presented in **Table 1**. Caffeine levels were all under 0.85

**Table 1.** Baseline characteristics of all participants ( $n=30$ )

	Mean $\pm$ S.D.
Age (years)	23.3 $\pm$ 6.6
BMI (kg/m <sup>2</sup> )	22.4 $\pm$ 2.4
Systolic blood pressure (mmHg)	126 $\pm$ 8
Diastolic blood pressure (mmHg)	71 $\pm$ 10
Heart rate (bpm)	62 $\pm$ 8
Glucose (mmol/L)	4.6 $\pm$ 0.7
Total cholesterol (mmol/L)	4.0 $\pm$ 0.6
Triglycerides (mmol/L)	1.19 $\pm$ 0.94
HDL-C (mmol/L)	1.33 $\pm$ 0.26
LDL-C (mmol/L)	2.19 $\pm$ 0.65

mg/L, indicating satisfactory compliance to the 24 hours caffeine abstinence. The annexin A5 targeting was not different between atorvastatin treatment ( $26.1 \pm 2.0\%$  and  $24.0 \pm 1.9\%$  respectively at 1 and 4 hours after reperfusion) and placebo treatment ( $25.6 \pm 2.4\%$  and  $24.5 \pm 2.2\%$ ) ( $p=0.999$ ) (**Fig. 2**).


Three day treatment with atorvastatin significantly reduced total cholesterol (from  $4.15 \pm 0.10$  mmol/L to  $3.44 \pm 0.10$  mmol/L) and LDL cholesterol (from  $2.31 \pm 0.10$  mmol/L to  $1.84 \pm 0.10$  mmol/L as compared to placebo treatment;  $p < 0.001$  for both comparisons). HDL cholesterol and triglyceride levels were unaffected by atorvastatin (from  $1.22 \pm 0.04$  to  $1.25 \pm 0.05$  for HDL-C, and from  $0.93 \pm 0.08$  to  $0.80 \pm 0.09$  for triglycerides).

Workload (50% of the maximal strength \* duration of ischaemic exercise) did not significantly differ between both study days ( $4260 \pm 284$  kg\*sec and  $4253 \pm 219$  kg\*sec after atorvastatin and placebo respectively ( $p=0.96$ ), indicating that potential differences in ischaemic challenge did not confound the observed lack of effect on annexin A5 targeting.

In the time control group ( $n=6$ ) the annexin A5 targeting after the first visit was  $23.5 \pm 5.5\%$  and  $23.2 \pm 6.5\%$  (respectively at 1 and 4 hours after reperfusion) and  $30.2 \pm 6.1\%$  and  $20.3 \pm 7.8\%$  after the second visit (**Fig. 3**). The between-subject standard deviations in annexin A5 targeting were 13.5%, 15.8%, 15.0% and 9.3% at 1 and 4 hours for visit 1 and 2 respectively. Within subject correlation was 0.93 and 0.79 at 1 and 4 hours respectively. This reproducibility should have allowed us to detect a difference in targeting between placebo and atorvastatin of at least 7%, closely resembling our initial power calculation.

## Discussion


The novel finding of this study is the lack of

**Fig. 2.** Annexin A5 targeting 1 and 4 hours after reperfusion, after placebo (open bars) and atorvastatin (closed bars) treatment. Bars represent mean  $\pm$  SE.

effect of atorvastatin on annexin A5 targeting after voluntary ischaemic exercise. This indicates that in our forearm model treatment with atorvastatin, in a dose and duration as previously used in clinical trials with patients who present with coronary syndromes<sup>21, 22, 32</sup>, does not modulate PS exposition after IR, in contrast to treatment with rosuvastatin, as reported recently<sup>31</sup>. As the protective action of atorvastatin in a setting of ischemia and reperfusion has been convincingly shown in multiple animal experiments<sup>33, 34</sup> and even in several clinical trials<sup>21, 22, 38</sup>, we conclude that PS modulation is not likely involved in the protective mechanism of atorvastatin.

During reperfusion after an ischaemic event, multiple detrimental processes take place simultaneously including formation of radical oxygen species (ROS), cellular and mitochondrial calcium overload, and a rapid increase (restoration) in pH<sup>39</sup>. These actions result in mitochondrial damage caused by opening of the mitochondrial permeability transition pore (MPTP), activation of caspases and subsequent cell damage and possible cell death (by either necrosis or apoptosis)<sup>40</sup>.

PS exposition is recognised to be part of the signalling cascade in the course of apoptosis<sup>41</sup>. It attracts phagocytes which remove the dying cell before its remnants evoke an inflammatory response<sup>42</sup>. The importance of PS exposition in developing tissue damage after IR injury was clearly demonstrated in several experiments where IR-injury could be reduced by



**Fig. 3.** Annexin A5 targeting 1 and 4 hours after reperfusion in time-control group (placebo treatment twice), after visit 1 (open bars) and visit 2 (closed bars). Bars represent mean  $\pm$  SE.

shielding of PS by diannexin treatment<sup>25, 26, 43</sup>).

The time-control experiment excluded a carry-over effect as a potential reason for the lack of observed effect of atorvastatin on annexin A5 targeting. In addition, interindividual SD and within subject correlation resulted in a power to detect differences between placebo and atorvastatin that resembles the results of our initial power calculation. In fact, based on these measurements we could calculate a minimal detectable difference of less than 10%, which is well below the previously observed effect of rosuvastatin on annexin A5 targeting. Thus, our sample size was sufficient to detect the effect size as expected from our hypothesis and previous observation with rosuvastatin.

The (cardio)protective mechanism of statins is well investigated, though its mechanism has not been fully elucidated<sup>44</sup>. Adenosine appears to play an important role in initiating the cascade (adenosine dependent phosphorylation of ERK1/2, Akt and eNOS) leading to a protective phenotype after statin therapy<sup>45</sup>. Upregulation of ecto-5'-nucleotidase has been shown *in vitro* and in animals *in-vivo* for various statins<sup>46</sup>. In humans *in-vivo* however, this effect has only been explored for rosuvastatin, which increases ecto-5'-nucleotidase activity with 50%<sup>47</sup>.

In our rosuvastatin trial participants were treated 7 days<sup>31</sup>, whereas in this atorvastatin trial participants were treated for 3 days. However we doubt that treat-

ment duration could account for the difference in annexin A5 targeting in these experiments. We have previously shown in humans that activation of ecto-5'-nucleotidase mediates prevention of PS exposure by rosuvastatin after IR. The effect of statins on ecto-5'-nucleotidase appears to occur rapidly<sup>6, 7</sup>. For example Sanada *et al.* found a significant increase of ecto-5'-nucleotidase activity in dogs for different statins (pravastatin, pitavastatin and cerivastatin) already 10 minutes after treatment<sup>7</sup>. Thus, our discrepant results between rosuvastatin and atorvastatin are not likely explained by differences in treatment duration but rather reflect a difference in pharmacodynamics between these two statins. There are significant differences between several statins in their efficacy to lower LDL cholesterol<sup>48</sup>. Moreover, pleiotropic effects have been shown to differ between lipophilic statins (e.g. atorvastatin) and hydrophilic statins (e.g. rosuvastatin). Lipophilic statins have been reported to render endothelial and vascular smooth muscle cells more susceptible to apoptosis than hydrophilic statins<sup>49</sup>. In humans rosuvastatin inhibits Rho/Rho kinase activity to a greater extent than atorvastatin at a dose that equally reduced LDL cholesterol<sup>36</sup>. Moreover hydrophilic statins have been suggested to be superior in reducing event rate after a primary acute coronary syndrome in normocholesterolemic patients<sup>50</sup>.

## Conclusion

Our results show that treatment with atorvastatin 80 mg does not reduce forearm PS exposition after ischaemic exercise. This suggests that the role of PS exposure in the prevention of ischemia and reperfusion injury by short term treatment with atorvastatin is limited.

## Acknowledgements

C.W.W. is an MD-medical research trainee funded by The Netherlands Organization for Health Research and Development (920-03-353). G.A.R. is a Clinical Established Investigator of the Netherlands Heart Foundation (2006 T035) and received an unrestricted research grant from Pfizer. For the remaining authors none were declared. Theseus Imaging Corporation, Boston, MA, USA provided GMP-graded annexin A5 for free.

## References

- 1) Lewis SJ, Moya LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, Limacher M, Kell S, Glasser SP, Grant J, Davis



- BR, Pfeffer MA, Braunwald E: Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. *Ann Intern Med*, 1998; 129: 681-689
- 2) Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) [see comments] [published erratum appears in *Diabetes Care* 1997 Jun; 20(6): 1048]. *Diabetes Care*, 1997; 20: 614-620
- 3) Sacks FM, Pfeffer MA, Moyer LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *N Engl J Med*, 1996; 335: 1001-1009
- 4) Saeki T, Sakuma N, Hayakawa K, Itou K, Wakami K, Tamai N, Kimura G: Low incidence of cardiac events in statin-administered patients in CAG study. *J Atheroscler Thromb*, 2009; 16: 172-178
- 5) Osman L, Amrani M, Isley C, Yacoub MH, Smolenski RT: Stimulatory effects of atorvastatin on extracellular nucleotide degradation in human endothelial cells. *Nucleosides Nucleotides Nucleic Acids*, 2006; 25: 1125-1128
- 6) Ledoux S, Laouari D, Essig M, Runembert I, Trugnan G, Michel JB, Friedlander G: Lovastatin enhances ecto-5'-nucleotidase activity and cell surface expression in endothelial cells: implication of rho-family GTPases. *Circ Res*, 2002; 90: 420-427
- 7) Sanada S, Asanuma H, Minamino T, Node K, Takashima S, Okuda H, Shinozaki Y, Ogai A, Fujita M, Hirata A, Kim J, Asano Y, Mori H, Tomoike H, Kitamura S, Hori M, Kitakaze M: Optimal windows of statin use for immediate infarct limitation: 5'-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase. *Circulation*, 2004; 110: 2143-2149
- 8) Urbich C, Dernbach E, Zeiher AM, Dimmeler S: Double-edged role of statins in angiogenesis signaling. *Circ Res*, 2002; 90: 737-744
- 9) Kolyada AY, Fedtsov A, Madias NE: 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors upregulate inducible NO synthase expression and activity in vascular smooth muscle cells. *Hypertension*, 2001; 38: 1024-1029
- 10) Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S: Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. *J Clin Invest*, 1998; 101: 2711-2719
- 11) Bolli R: Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. *J Mol Cell Cardiol*, 2001; 33: 1897-1918
- 12) Sack MN, Yellon DM: Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation. *J Am Coll Cardiol*, 2003; 41: 1404-1407
- 13) Bell RM, Yellon DM: Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. *J Am Coll Cardiol*, 2003; 41: 508-515
- 14) Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, Wen J, Takeshita A: Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. *Circulation*, 2002; 105: 868-873
- 15) Gueler F, Rong S, Park JK, Fiebeler A, Menne J, Elger M, Mueller DN, Hampich F, Dechend R, Kunter U, Luft FC, Haller H: Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. *J Am Soc Nephrol*, 2002; 13: 2288-2298
- 16) Jones SP, Gibson ME, Rimmer DM, III, Gibson TM, Sharp BR, Lefer DJ: Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. *J Am Coll Cardiol*, 2002; 40: 1172-1178
- 17) Yokota N, O'Donnell M, Daniels F, Burne-Taney M, Keane W, Kasiske B, Rabb H: Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury. *Am J Nephrol*, 2003; 23: 13-17
- 18) Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. *JAMA*, 2001; 285: 1711-1718
- 19) De Denus S, Spinler SA: Early statin therapy for acute coronary syndromes. *Ann Pharmacother*, 2002; 36: 1749-1758
- 20) Dohi T, Miyauchi K, Okazaki S, Yokoyama T, Yanagisawa N, Tamura H, Kojima T, Yokoyama K, Kurata T, Daida H: Higher baseline LDL-C levels amplify the short-term benefit of early intensive statin treatment in acute coronary syndrome. *J Atheroscler Thromb*, 2011; 18: 42-48
- 21) Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A, Di SG: Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. *J Am Coll Cardiol*, 2007; 49: 1272-1278
- 22) Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A: Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. *J Am Coll Cardiol*, 2009; 54: 558-565
- 23) Thimister PW, Hofstra L, Liem IH, Boersma HH, Kemerink G, Reutelingsperger CP, Heidendal GA: In vivo detection of cell death in the area at risk in acute myocardial infarction. *J Nucl Med*, 2003; 44: 391-396
- 24) Narula J, Strauss HW: Invited commentary: P.S.\* I love you: implications of phosphatidyl serine (PS) reversal in acute ischemic syndromes. *J Nucl Med*, 2003; 44: 397-399
- 25) Teoh NC, Ito Y, Field J, Bethea NW, Amr D, McCuskey MK, McCuskey RS, Farrell GC, Allison AC: Diannexin, a novel annexin V homodimer, provides prolonged protection against hepatic ischemia-reperfusion injury in

- mice. *Gastroenterology*, 2007; 133: 632-646
- 26) Wever KE, Wagener FADTG, Frielink C, Boerman OC, Scheffer GJ, Allison A, Masereeuw R, Rongen GA: Diannexin Protects against Renal Ischemia Reperfusion Injury and Targets Phosphatidylserines in Ischemic Tissue. *PLoS ONE*, 2011; 6: e24276. doi:10.1371/journal.pone.0024276
- 27) Hale SL, Allison AC, Kloner AR: Diannexin reduces no-reflow after reperfusion in rabbits with large ischemic myocardial risk zones. *Cardiovasc Ther*, 2011; 29: e42-52. doi: 10.1111/j.1755-5922.2010
- 28) Rongen GA, Oyen WJ, Ramakers BP, Riksen NP, Boerman OC, Steinmetz N, Smits P: Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle preconditioning in humans. *Circulation*, 2005; 111: 173-178
- 29) Riksen NP, Zhou Z, Oyen WJ, Jaspers R, Ramakers BP, Brouwer RM, Boerman OC, Steinmetz N, Smits P, Rongen GA: Caffeine prevents protection in two human models of ischemic preconditioning. *J Am Coll Cardiol*, 2006; 48: 700-707
- 30) Riksen NP, Oyen WJ, Ramakers BP, van den Broek PH, Engbersen R, Boerman OC, Smits P, Rongen GA: Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans. *Clin Pharmacol Ther*, 2005; 78: 52-59
- 31) Meijer P, Oyen WJ, Dekker D, van den Broek PH, Wouters CW, Boerman OC, Scheffer GJ, Smits P, Rongen GA: Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection. *Arterioscler Thromb Vasc Biol*, 2009; 29: 963-968
- 32) Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di SG: Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. *Circulation*, 2004; 110: 674-678
- 33) Atar S, Ye Y, Lin Y, Freeberg SY, Nishi SP, Rosanio S, Huang MH, Uretsky BF, Perez-Polo JR, Birnbaum Y: Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. *Am J Physiol Heart Circ Physiol*, 2006; 290: H1960-H1968
- 34) Birnbaum Y, Lin Y, Ye Y, Merla R, Perez-Polo JR, Uretsky BF: Pretreatment with high-dose statin, but not low-dose statin, and ezetimibe, limits infarct size in the rat. *J Cardiovasc Pharmacol Ther*, 2008; 13: 72-79
- 35) Naoumova RP, Dunn S, Rallidis L, bu-Muhana O, Newirth C, Rendell NB, Taylor GW, Thompson GR: Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. *J Lipid Res*, 1997; 38: 1496-1500
- 36) Rawlings R, Nohria A, Liu PY, Donnelly J, Creager MA, Ganz P, Selwyn A, Liao JK: Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. *Am J Cardiol*, 2009; 103: 437-441
- 37) Schreiber-Deturmeny E, Bruguerolle B: Simultaneous high-performance liquid chromatographic determination of caffeine and theophylline for routine drug monitoring in human plasma. *J Chromatogr B Biomed Appl*, 1996; 677: 305-312
- 38) Chyrchel M, Rakowski T, Rzeszutko L, Legutko J, Dziewierz A, Dubiel JS, Dudek D: Effects of high-dose statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome. *Kardiologia Pol*, 2006; 64: 1357-1362
- 39) Yellon DM, Hausenloy DJ: Myocardial reperfusion injury. *N Engl J Med*, 2007; 357: 1121-1135
- 40) Javadov S, Karmazyn M: Mitochondrial permeability transition pore opening as an endpoint to initiate cell death and as a putative target for cardioprotection. *Cell Physiol Biochem*, 2007; 20: 1-22
- 41) Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, Green DR: Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. *J Exp Med*, 1995; 182: 1545-1556
- 42) Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM: Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. *J Immunol*, 1992; 148: 2207-2216
- 43) Shen XD, Ke B, Zhai Y, Tsuchihashi SI, Gao F, Duarte S, Coito A, Busuttill RW, Allison AC, Kupiec-Weglinski JW: Diannexin, a novel annexin v homodimer, protects rat liver transplants against cold ischemia-reperfusion injury. *Am J Transplant*, 2007; 7: 2463-2471
- 44) Ludman A, Venugopal V, Yellon DM, Hausenloy DJ: Statins and cardioprotection--more than just lipid lowering? *Pharmacol Ther*, 2009; 122: 30-43
- 45) Merla R, Ye Y, Lin Y, Manickavasagam S, Huang MH, Perez-Polo RJ, Uretsky BF, Birnbaum Y: The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation. *Am J Physiol Heart Circ Physiol*, 2007; 293: H1918-H1928
- 46) Osman L, Amrani M, Ilsley C, Yacoub MH, Smolenski RT: Atorvastatin accelerates extracellular nucleotide degradation in human endothelial cells. *Mol Cell Biochem*, 2008; 308: 209-217
- 47) Meijer P, Wouters CW, van den Broek PH, de RM, Scheffer GJ, Smits P, Rongen GA: Upregulation of ecto-5'-nucleotidase by rosuvastatin increases the vasodilator response to ischemia. *Hypertension*, 2010; 56: 722-727
- 48) Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR<sup>®</sup> Trial). *Am J Cardiol*, 2003; 92: 152-160
- 49) Katsiki N, Tziomalos K, Chatzizisis Y, Elisaf M, Hatzitolios AI: Effect of HMG-CoA reductase inhibitors on vascular cell apoptosis: beneficial or detrimental? *Atherosclerosis*, 2010; 211: 9-14
- 50) Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, Sakaino N, Kitagawa A: Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction: subanalysis of MUSASHI-AMI. *Circ J*, 2007; 71: 1348-1353